CEO of The James to Discuss Future of Cancer Research, Prevention, Treatment

January 16, 2013

COLUMBUS, Ohio –Dr. Michael Caligiuri, director of The Ohio State University Comprehensive Cancer Center and CEO of the Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC-James), will discuss the future of cancer research, prevention, and treatment during a free event at 6 p.m. Jan. 24 at The Fawcett Center, 2400 Olentangy River Road.

Caligiuri will discuss new cancer therapies and discoveries being made at Ohio State, as well as progress toward creating a cancer-free world.

This event is open to cancer survivors, their caregivers, friends and health professionals. The event is free, but registration is required. For more information or to register, contact JamesCare for Life at 614-293-6428.

The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute strives to create a cancer-free world by integrating scientific research with excellence in education and patient-centered care, a strategy that leads to better methods of prevention, detection and treatment. Ohio State is one of only 41 National Cancer Institute (NCI)-designated Comprehensive Cancer Centers and one of only seven centers funded by the NCI to conduct both phase I and phase II clinical trials. The NCI recently rated Ohio State’s cancer program as “exceptional,” the highest rating given by NCI survey teams. As the cancer program’s 210-bed adult patient-care component, The James is a “Top Hospital” as named by the Leapfrog Group and one of the top cancer hospitals in the nation as ranked by U.S. News & World Report.

# # #

Contact: Alexis Shaw, Wexner Medical Center Public Affairs and Media Relations, 614-293-3737 or

Contact Media Staff

Amanda Harper

Director of Media Relations

614-685-5420 (direct)

614-293-3737 (main)

Media staff are available by calling 614-293-3737 Monday through Friday between 8 a.m. and 5 p.m.


If after hours, please call 614-293-8000 (ask the operator to page the hospital administrative manager).

Latest News

Drug Harnesses Immune System To Combat Most Common Form of Lung Cancer

Recently approved immunotherapy drugs are offering patients – and their oncologists – new hope for extending survival of people with advanced non-small cell lung cancer (NSCLC).

Investigational Drug May Prevent Life-Threatening Muscle Loss in Advanced Cancers

New data describes how an experimental drug can stop life-threatening muscle wasting (cachexia) associated with advanced cancers and restore muscle health. The experimental agent, known as AR-42 while in...

One Day to Help Create More Healthy — And Cancer-Free — Tomorrows

Through the generous support of Don and Angie Ward, all donations made to Ohio State's cancer program today (Nov. 24) through Giving Tuesday (Dec. 1), will be matched, 100 percent, up to $50,000.